CN103509102A - 野生型人生长激素突变体 - Google Patents
野生型人生长激素突变体 Download PDFInfo
- Publication number
- CN103509102A CN103509102A CN201210198920.XA CN201210198920A CN103509102A CN 103509102 A CN103509102 A CN 103509102A CN 201210198920 A CN201210198920 A CN 201210198920A CN 103509102 A CN103509102 A CN 103509102A
- Authority
- CN
- China
- Prior art keywords
- primer
- growth hormone
- wild
- hgh
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title description 24
- 108010000521 Human Growth Hormone Proteins 0.000 title description 24
- 239000000854 Human Growth Hormone Substances 0.000 title description 24
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 229960002989 glutamic acid Drugs 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 102000018997 Growth Hormone Human genes 0.000 abstract description 9
- 108010051696 Growth Hormone Proteins 0.000 abstract description 9
- 239000000122 growth hormone Substances 0.000 abstract description 9
- 230000004071 biological effect Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000009614 wildtype growth Effects 0.000 abstract 2
- 230000012010 growth Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 16
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 206010062767 Hypophysitis Diseases 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 108020005038 Terminator Codon Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002745 epiphysis Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100022831 Somatoliberin Human genes 0.000 description 3
- 101710142969 Somatoliberin Proteins 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003054 facial bone Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
A | B | C(EC50) | D | |
Wild Type | 0.38683 | 0.97738 | 62.41051 | 1.18484 |
Mutant1 | 0.3935 | 0.94341 | 30.59938 | 1.30384 |
Mutant2 | 0.40064 | 0.98 | 16.45342 | 1.23912 |
Mutant3 | 0.39798 | 0.99938 | 31.619 | 1.21946 |
Mutant4 | 0.37564 | 0.92167 | 31.58003 | 1.3006 |
Mutant5 | 0.37548 | 0.94143 | 8.08501 | 1.23807 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210198920.XA CN103509102B (zh) | 2012-06-15 | 2012-06-15 | 野生型人生长激素突变体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210198920.XA CN103509102B (zh) | 2012-06-15 | 2012-06-15 | 野生型人生长激素突变体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103509102A true CN103509102A (zh) | 2014-01-15 |
CN103509102B CN103509102B (zh) | 2015-07-22 |
Family
ID=49892575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210198920.XA Active CN103509102B (zh) | 2012-06-15 | 2012-06-15 | 野生型人生长激素突变体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103509102B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018004294A3 (ko) * | 2016-06-30 | 2018-08-09 | 주식회사 크레아플래닛 | 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
CN112239760A (zh) * | 2020-09-18 | 2021-01-19 | 深圳科兴药业有限公司 | 高效表达重组hGH的重组工程菌及构建方法和应用 |
CN113880954A (zh) * | 2021-09-29 | 2022-01-04 | 江苏大学 | 一种重组人生长激素及其构建方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1269805A (zh) * | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
WO2012010516A1 (en) * | 2010-07-22 | 2012-01-26 | Novo Nordisk Health Care Ag | Growth hormone conjugates |
-
2012
- 2012-06-15 CN CN201210198920.XA patent/CN103509102B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1269805A (zh) * | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
WO2012010516A1 (en) * | 2010-07-22 | 2012-01-26 | Novo Nordisk Health Care Ag | Growth hormone conjugates |
Non-Patent Citations (2)
Title |
---|
ROYTRAKUL,S.ET AL.: "AAK69708", 《NCBI》, 23 May 2003 (2003-05-23) * |
李伟 等: "人生长激素突变体的制备及其对受体亲和力和生物活性的研究", 《细胞生物学杂志》, 31 December 2003 (2003-12-31) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018004294A3 (ko) * | 2016-06-30 | 2018-08-09 | 주식회사 크레아플래닛 | 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
CN112239760A (zh) * | 2020-09-18 | 2021-01-19 | 深圳科兴药业有限公司 | 高效表达重组hGH的重组工程菌及构建方法和应用 |
CN113880954A (zh) * | 2021-09-29 | 2022-01-04 | 江苏大学 | 一种重组人生长激素及其构建方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103509102B (zh) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106421749A (zh) | 包括酪蛋白衍生肽的药物组合物及其使用方法 | |
CN103906440A (zh) | 乳清蛋白胶束用于处于肥胖症或糖尿病风险中的婴儿的用途 | |
CN106661087A (zh) | 用于改善哺乳动物血糖控制的肽及其组合物 | |
CN103509102B (zh) | 野生型人生长激素突变体 | |
JP4132635B2 (ja) | 未失活酵素強化組成物 | |
CN101553127A (zh) | 用于改善繁殖效率的家畜管理 | |
CN113455651A (zh) | 一种含有干细胞提取液的代谢和免疫增强及改善亚健康制剂 | |
CN106172185A (zh) | 一种犊牛一体化饲养方法 | |
JP3691685B2 (ja) | 血糖値上昇抑制剤 | |
CN108575887A (zh) | 一种肉猪的生态养殖法 | |
CN112956702A (zh) | 一种增加骨密度的复合制剂 | |
CN110312510A (zh) | 肌纤维化抑制用组合物 | |
WO2010043073A1 (zh) | 一种胶原多肽及其制备方法和应用 | |
CN101503727B (zh) | 三角帆蚌酶解多肽及其制备和应用 | |
CN116082454A (zh) | 一种具有骨密度调节活性的多肽及其应用 | |
JPH06510292A (ja) | 慢性肝疾患治療剤 | |
CN108623655B (zh) | 改善胰岛素抵抗的二肽el及其用途 | |
JP7286335B2 (ja) | 骨密度改善用食品組成物、骨密度改善剤、前駆骨芽細胞増殖用食品組成物、骨分化促進用食品組成物、骨強化用食品組成物、抗骨粗鬆症用食品組成物、前駆骨芽細胞増殖剤、骨分化促進剤、骨強化剤、抗骨粗鬆症剤、骨密度改善剤の製造方法、前駆骨芽細胞増殖剤の製造方法、骨分化促進剤の製造方法、骨強化剤の製造方法及び抗骨粗鬆症剤の製造方法 | |
JP7074995B2 (ja) | 線維芽細胞増殖促進剤及び線維芽細胞におけるエラスチン産生促進剤 | |
CN1072955C (zh) | 黑羊胎素补液及其生产方法 | |
CN100535005C (zh) | 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法 | |
CN105348380B (zh) | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 | |
JP5791066B2 (ja) | 上皮細胞の増殖促進方法、及び上皮細胞の増殖促進剤 | |
CN114712481B (zh) | 一种复合植物源多肽及其制备方法与应用 | |
CN102397534B (zh) | 胰岛素在制备促进颌骨组织愈合的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161219 Address after: 201203 Shanghai City, Pudong New Area hi tech Bing Road No. 301 Patentee after: Shanghai metech junao Biological Technology Co. Ltd. Address before: Shanghai city 201203 libing road Pudong New Area Zhangjiang hi tech Park No. 399 Patentee before: Guo Huaizu |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Wild type human growth hormone mutant Effective date of registration: 20190322 Granted publication date: 20150722 Pledgee: Shanghai Baimai Pharmaceutical Co.,Ltd. Pledgor: Shanghai metech junao Biological Technology Co. Ltd. Registration number: 2019310000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210119 Granted publication date: 20150722 Pledgee: Shanghai Biomabs Pharmaceuticals Co.,Ltd. Pledgor: SHANGHAI MAITAI JUNAO BIOTECHNOLOGY Co.,Ltd. Registration number: 2019310000007 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210305 Address after: Room 417, 4th floor, tower 2, Lippo centre, 89 Queensway, Hong Kong, China Patentee after: Hong Kong Sansheng Pharmaceutical Co.,Ltd. Address before: 301 Li Bing Road, Zhangjiang Gaoke, Pudong New Area, Shanghai Patentee before: SHANGHAI MAITAI JUNAO BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210730 Address after: No. 14, Yayuan Road, Bantian street, Longgang District, Shenzhen, Guangdong Patentee after: SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL Co.,Ltd. Address before: Room 417, 4th floor, tower 2, Lippo centre, 89 Queensway, Hong Kong, China Patentee before: Hong Kong Sansheng Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |